Preparation, characterization and in vitro evaluation of PEGylated nanoliposomal containing etoposide on lung cancer

References

• Cheong I, Zhou S. Tumor-specific liposomal drug release mediated by liposomase. Methods Enzymol. 2009;465:251–265.
   PubMed Web of Science ®Google Scholar
• Mohanty C, Das M, R Kanwar J, et al. Receptor mediated tumor targeting: an emerging approach for cancer therapy. CDD. 2011;8:45–58.
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175–180.
   PubMed Web of Science ®Google Scholar
• Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett. 2007;252:9–18.
   PubMed Web of Science ®Google Scholar
• Benita S. editor. Microencapsulation: methods and industrial applications. Boca Raton: CRC Press; 2005.
   Google Scholar
• Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. IJERPH. 2012;9:2444–2453.
   Web of Science ®Google Scholar
• Chen J, Gu W, Yang L, et al. Nanotechnology in the management of cervical cancer. Rev Med Virol. 2015;25:72–83.
   PubMed Web of Science ®Google Scholar
• Eskolaky EB, Ardjmand M, Akbarzadeh A. Evaluation of anti-cancer properties of pegylated ethosomal paclitaxel on human melanoma cell line SKMEL-3. Trop J Pharm Res. 2015;14:1421–1425.
   Web of Science ®Google Scholar
• Ross JS. Targeted therapies for cancer. In: Ginsburg GS, Willard HF, editors. Essentials of genomic and personalized medicine 2010. Academic Press; p. 532–547.
   Google Scholar
• Rostas JW, Dyess DL. Current operative management of breast cancer: an age of smaller resections and bigger cures. Int J Breast Cancer. 2012;2012:1.
   Google Scholar
• Mehrabi M, Esmaeilpour P, Akbarzadeh A, et al. Efficacy of pegylated liposomal etoposide nanoparticles on breast cancer cell lines. Turk J Med Sci. 2016;46:567–571.
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vascularture: the key role of tumor-selective macromolecular drug targeting. Advan Enzyme Regul. 2001;41:207.
   Google Scholar
• Izadi M, Ebrahimi Shahemabadi H, Kanaani L. Investigation of characteristics of loaded carboplatin on the liposomal nanoparticles on the cell carcinoma of the human brain c6. Adv Biores. 2016;7:113–118.
   Google Scholar
• Chiani M, Shokrgozar MA, Azadmanesh K, et al. Preparation, characterization, and in vitro evaluation of bleomycin‐containing nanoliposomes. Chem Biol Drug Des. 2017;89:492–497.
   PubMed Web of Science ®Google Scholar
• Dadgar N, Esfahani MK, Torabi S, et al. Liposomal drug delivery systems and anticancer drugs. Molecules. 2018;23:907.
   PubMed Web of Science ®Google Scholar
• Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26:57–64.
   PubMed Web of Science ®Google Scholar
• Allen TM, Martin FJ. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol. 2004;31:5–15. WB Saunders.
   PubMed Web of Science ®Google Scholar
• Poy D, Akbarzadeh A, Ebrahimi Shahmabadi H, et al. Preparation, characterization, and cytotoxic effects of liposomal nanoparticles containing cisplatin: an in vitro study. Chem Biol Drug Des. 2016;88:568–573.
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
   PubMed Web of Science ®Google Scholar
• Ebrahimifar M, Nili-Ahmadabadi A, Akbarzadeh A, et al. Preparation, characterization and cytotoxic effects of pegylated nanoliposomal containing carboplatin on ovarian cancer cell lines. Ind J Clin Biochem. 2017;32:230–234.
   PubMed Web of Science ®Google Scholar
• Chiani M, Toofani Milani A, Nemati M, et al. Anticancer effect of cisplatin-loaded poly (Butylcyanoacrylate) nanoparticles on A172 brain cancer cells line. Asian Pac J Cancer Prev. 2019;20:303–309.
   PubMedGoogle Scholar
• Guideline IH. Validation of analytical procedures: text and methodology Q2 (R1). Geneva (Switzerland): ICH; 2005, Vol. 10, p. 11–12.
   Google Scholar
• Bhusari SS, Borse G, Wakte P. Development and Validation of UV-Visible Spectrophotometric method for simultaneous estimation of Etoposide and Picroside-II in bulk and pharmaceutical formulation. JDDT. 2019;9:257–262.
   Google Scholar
• Panwar P, Pandey B, Lakhera PC, et al. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomedicine. 2010;5:101.
   PubMed Web of Science ®Google Scholar
• Esmaeili Govarchin Ghaleh H, Zarei L, Mansori Motlagh B, et al. Using CuO nanoparticles and hyperthermia in radiotherapy of MCF-7 cell line: synergistic effect in cancer therapy. Int J Nanomedicine. 2019;47:1396–1403.
   Google Scholar
• Gayam SR, Venkatesan P, Sung YM, et al. An NAD (P) H: quinone oxidoreductase 1 (NQO1) enzyme responsive nanocarrier based on mesoporous silica nanoparticles for tumor targeted drug delivery in vitro and in vivo. Nanoscale. 2016;8:12307–12317.
   PubMed Web of Science ®Google Scholar
• Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2012;64:246–255.
   Web of Science ®Google Scholar
• Na K, Lee SA, Jung SH, et al. Elastin-like polypeptide modified liposomes for enhancing cellular uptake into tumor cells. Colloids Surf B Biointerfaces. 2012;91:130–136.
   PubMed Web of Science ®Google Scholar
• Awasthi VD, Garcia D, Goins BA, et al. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm. 2003;253:121–132.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61:91–112.
   PubMed Web of Science ®Google Scholar
• Koning GA, Eggermont AM, Lindner LH, et al. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res. 2010;27:1750–1754.
   PubMed Web of Science ®Google Scholar
• Yousefi A, Esmaeili F, Rahimian S, et al. Preparation and in vitro evaluation of a pegylated nano-liposomal formulation containing docetaxel. Sci Pharm. 2009;77:453–464.
   Google Scholar
• Dua JS, Rana AC, Bhandari AK. Liposome: methods of preparation and applications. Int J Pharm Stud Res. 2012;3:14–20.
   Google Scholar
• Mishra PR, Al Shaal L, Müller RH, et al. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm. 2009;371:182–189.
   PubMed Web of Science ®Google Scholar
• Martins S, Tho I, Ferreira DC, et al. Physicochemical properties of lipid nanoparticles: effect of lipid and surfactant composition. Drug Dev Ind Pharm. 2011;37:815–824.
   PubMed Web of Science ®Google Scholar
• Gharib A, Faezizadeh Z, Godarzee M. Preparation and characterization of nanoliposomal beta-cryptoxanthin and its effect on proliferation and apoptosis in human leukemia cell line K562. Trop J Pharm Res. 2015;14:187–194.
   Web of Science ®Google Scholar
• Kang C, Sun Y, Zhu J, et al. Delivery of nanoparticles for treatment of brain tumor. Curr Drug Metab. 2016;17:745–754.
   PubMed Web of Science ®Google Scholar
• Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.
   PubMed Web of Science ®Google Scholar
• Chiani M, Norouzian D, Shokrgozar MA, et al. Folic acid conjugated nanoliposomes as promising carriers for targeted delivery of bleomycin. Artif Cells Nanomed Biotechnol. 2018;46:757–763.
   PubMed Web of Science ®Google Scholar
• Cotter TG, Lennon SV, Glynn JG, et al. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res. 1990;10:1153–1159.
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells measured by flow cytometry. Cytometry A. 1992;13:795–808.
   Web of Science ®Google Scholar